Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans

Pharmacogenetics

Volumn 10, Issue 5, 2000, Pages 415-424

  Paulussen, Aimée ^a   Lavrijsen, Karel ^a   Bohets, Hilde ^a   Hendrickx, Jan ^a   Verhasselt, Peter ^a   Luyten, Walter ^a   Konings, Frank ^a   Armstrong, Martin ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

CYP3A5; Gene; Metabolism; Polymorphism expression

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A5; MIDAZOLAM; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; LIVER MICROSOME; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

5' UNTRANSLATED REGIONS; ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; HUMANS; ISOENZYMES; LINKAGE (GENETICS); MICROSOMES, LIVER; MIDAZOLAM; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; REGULATORY SEQUENCES, NUCLEIC ACID; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VARIATION (GENETICS);

STAPHYLOCOCCUS PHAGE 3A;

EID: 0033932053     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200007000-00005     Document Type: Article

References (25)

1. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, et al. Cytochrome P450 hPCN3, a novel cytochrome P450IIIA gene product that is differentially expressed in adult human liver. J Biol Chem 1989; 264: 10388-10395.
2. Barwick JL, Quattrochi LC, Mills AS, Potenza C, Tukey RH, Guzelian PS. Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. Mol Pharmacol 1996; 50:10-16.
3. Boobis AR, Edwards RJ. Adams DA, Davies DS. Dissecting the function of cytochrome P450. Br J Clin Pharmacol 1996; 42:81-89.
4. Cholerton S, Daley AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992; 13:434-439.
5. Fujii-Kuriyama Y, Imataka H, Sogawa K, Yasumoto KI, Kikuchi Y. Regulation of CYP1A1 expression. FASEB J 1992; 6:706-710.
6. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 (CYP3A) subfamily. Biochem Pharmacol 1994; 47:1643-1653.
7. Guengerich FP. Characterisation of human cytochrome P450 enzymes. FASEB 1992; 6:745-748.
8. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, Hall SD. Bimodal distribution of renal cytochrome P450 3 A activity in humans. Mol Pharmacol 1996; 50:52-59.
9. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T. Gene structure of CYP3A4, an adult specific form of cytochrome P450 in human livers and its transcriptional regulation. Eur J Biochem 1993; 218:585-595.
10. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, Hankinson O. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 1991; 252:954-958.
11. Hoyo-Vadillo C, Castenada-Hernandez G, Herrera JE. Vidal-Garate J. Moreno-Ramos A, Chavez F, Hong E. Pharmacokinetics of nifedipine slow release tablets in Mexican patients: further evidence for an oxidative polymorphism. J Clin Pharmacol 1989; 29:816-820.
12. Imataka H, Nakayama K, Yasumoto K, Mizuno A, Fujii-Kuriyama Y. Hayami M. Cell-specific translational control of transcription factor BTEB expression. The role of an upstream AUG in the 5′ untranslated region. J Biol Chem 1994; 269:20668-20673.
13. Itoh S, Yangimoto T, Tagawa S, Hashimoto H, Kitamura R, Nakajima Y, et al. Genomic organisation of human fetal specific P-450IIA7 (cytochrome P-450HFLa)-related gene(s) and interaction of transcriptional regulatory factor with its DNA element in the 5′ flanking region. Biochim Biophys Acta 1992; 1130:133-138.
14. Jounaidi Y, Guzelian PS, Maurel P, Vilarem MJ. Sequence of the 5′-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochcin Biophys Res Commun 1994; 205:1741-1747.
15. Komori M, Nishio K, Kitada M, Shiramatsu K, Muroya K, Soma M, et al. Fetus specific expression of a form of cytochrome P-450 in human livers. Biochemistry 1990; 29:4430-4433.
16. Lavrijsen K, Van Houdt J, Thijs D, Meuldermans W, Heykants J. Induction potential of antifungals containing an imidazole or triazole moiety. Miconazole and ketoconazole, but not itraconazole are able to induce hepatic drug metabolising enzymes of male rats at high doses. Biochem Pharmacol 1986; 35:1867-78.
17. Miller GL. Protein determination for large numbers of samples. Anal Chem 1959; 31:964.
18. Nebert DW. The Ah locus: genetic differences in toxicity, cancer, mutation and birth defects. Crit Rev Toxicol 1989; 20:153-174.
19. Renwick AG, Robertson DRC, Macklin B, Challenor V, Waller DG, George CF. The pharmacokinetics of oral nifedipine - a population study. Br J Clin Pharmacol 1988; 25:701-708.
20. Schellens JHM, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 1988; 37:2507-2510.
21. Schuetz J. Beach P, Guzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994; 4:11-20.
22. Shimada T, Guengerich FP. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc Natl Acad Sci USA 1989; 86:462-465.
23. Sogawa K, Kikuchi Y, Imataka H, Fujii-Kuriyama Y. Comparison of DNA-binding properties between BTEB and Sp 1. Biochemistry 1993; 114:605-609.
24. Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992; 21:511-526.
25. Wrighton SA, Brian WR, Sari MA, Iwasaki M. Guengerich FP, Raucy JL, et al. Studies in the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38:207-213.